|
ISIN No
|
INE942C01045
|
BSE Code / NSE Code
|
506879 / GUJTHEM
|
Book Value (Rs.)
|
24.27
|
Face Value
|
1.00
|
|
Bookclosure
|
05/09/2025
|
52Week High
|
479
|
EPS
|
4.48
|
P/E
|
69.57
|
|
Market Cap.
|
3393.18 Cr.
|
52Week Low
|
208
|
P/BV / Div Yield (%)
|
12.83 / 0.22
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| Gujarat Themis Biosyn Ltd. was incorporated in 1981 jointly by GIIC and chemosyn (P) Ltd. GIBL commenced production in Aug.1985 by producing antibiotic erythromycin, and erythromycin salts and formulations. GTBL was a sick company which was forced to discontinue production because of accumulated losses. The company was takenover during June 1991 by pharmaceutical Business Group India Ltd; a unique consortium of five competing drug companies - Themis Chemicals, Kopran, Anant & Co., Cadila and Lyka Labs. The company has technical and financial collaboration with Yuhan Corporation, South Korea. With Yuhan's knowhow, GTBL has become India's first company to start commercial production of anti-tubercolis drug, rifampicin.
2002-Gujarat Themis Biosyn Ltd has informed that Mr Rajneesh Anand has been appointed as the Managing Director of the Company w e f February 01, 2002.
2008
-Gujarat Themis Biosyn Ltd has appointed Mr. S S Lee as an Additional Director of the Company.
-The Company has appointed Mr. Rajneesh Anand as Managing Director
2010
- Gujarat Themis Biosyn Ltd has appointed Mr. Subhash C Kaushik as Additional Director of the Company.
2011
-The Board of Directors appointed Mr. Rajneesh Anand as Managing Director of the Company
2012
-The Company has received a Rehabilitation Scheme approved by the Board of Industrial and Financial Reconstruction (BIFR)
2014
-Mr. Vikas Tarekar has been appointed as a Company Secretary of the company.
-Mr. Tapas Guha has been appointed as a CEO of the Company.
2023
-The Company has splits its face value from Rs. 5/- to Rs. 1/-.
2024 -The Company has issued Bonus Shares in the Ratio of 1:2. -The Company has approved the Scheme of Amalgamation of Gujarat Themis Biosyn Ltd. with Themis Medicare Ltd. 2025 -The Company has listed his 10,89,65,265 equity shares of face value of Rs.1/- each, fully paid up in National Stock Exchange (NSE)
|